Claims against Bayer's One-A-Day vitamins proceed in court; Tech glitches in Open Payments database plaguing pharma;

@FiercePharma: Gates Foundation puts $52 million behind CureVac, following Sanofi, Boehringer's lead. FierceVaccines story | Follow @FiercePharma

@EricPFierce: Texas drug compounder corralled by federal injunction. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Should Teva buy Mylan? 'Close call,' analyst says. Report | Follow @CarlyHFierce

> Plaintiffs suing Bayer over its One-A-Day vitamins can proceed with their claims that the products falsely stated they could boost physical energy, but a judge has dismissed similar heart-health and immunity claims. Report

> Medicare officials say some technical glitches in its Open Payments database system are interfering with pharma's ability to file information on financial relationships with doctors and hospitals. Report

> Generics maker Mylan ($MYL) has launched a range of pain-fighting Fentanyl patches in various doses, adding to its current product line in the area. Release

> With an aging population, pharma stocks will make up an increasingly large chunk of equity indices, a top hedge fund executive figures. Report

> The Dutch pension fund of U.S. pharmaceutical company Johnson & Johnson ($JNJ) has completed a transfer to Belgium after a three-year process. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Brain-controlled, robotic prosthetic hand comes closer to simulating reality. Article | Follow @FierceMedDev

@VarunSaxena2: Irish research center wins EU funding to study and develop transdermal delivery methods. More from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: Some background info on liquid biopsies. More from MIT Technology Review | Follow @EmilyWFierce

> LifeMap CEO: Apple's ($AAPL) ResearchKit 'unshackles science.' More

> Scientists tout positive results for Alzheimer's ultrasound therapy in mice. Article

> Startup raises $3.9M to market device-app combo to calm panic disorder. Report

Biotech News

@FierceBiotech: Acadia craters as takeover buzz is silenced by news of an unexpected NDA delay, CEO exit. Article | Follow @FierceBiotech

@JohnCFierce: 4 of the last Fierce 15 have filed IPOs since last fall. More coming. Hot market, eh? Feature | Follow @JohnCFierce

@DamianFierce: Here's the $ENDP letter to $SLXP's board, pitching a deal that's 74% stock. PDF | Follow @DamianFierce

> Epizyme ($EPZM) retrieves global rights to cancer drug in $110M deal. News

> Neuralstem ($CUR) tanks on cloudy results for its ALS treament. Story

> 23andMe dives into biotech with Genentech R&D star Richard Scheller on board. Report

Vaccines News

> Analyst: Ebola vaccine developers 'need to weigh risks' as cases dwindle. More

> Combo-happy Diamyd launches new diabetes vaccine trial in children. Report

> Smallpox vaccine helps Bavarian Nordic net first full-year profit in 5 years. Story

> Takeda transfers HPV vaccine rights as it continues globalization push. More

> Bharat's $1 rotavirus vaccine rolls out in India to challenge GSK, Merck. Article

Pharma Manufacturing News

> Hikma profits soften as shortages of doxycycline are resolved. Article

> Mylan recalls drug after problem uncovered with Indian supplier. Item

> Texas compounder corralled by federal injunction. More

> Pfizer ($PFE) makes it official, it has reversed its decision to close Irish Lipitor plant. Story

> Manufacturing mess at Johnson & Jonhson ($JNJ) consumer plant results in guilty plea, $20M fine. Report

Pharma Asia News

> AstraZeneca ($AZN) and Singapore's A*STAR ink research pact on complex heart failure syndrome. More

> Biotech in China is built brick-by-brick, but more money would help, BeiGene's Oyler says. Article

> First off the blocks, Natco gets India's regulatory nod for hep C copy. Story

> Japan a lucrative market for endocrine sales, report says. Item

> Glaxo ($GSK) plants a flag in Singapore with CEO Witty on hand. Report

And Finally... Copay info service NeedyMeds has added generics savings programs to its database. Release